About Regulon Company
Regulon, a company specializing in the development of biopharmaceutical technologies, is an oncology-oriented company with its own developments based on tumor-targeting nanotechnologies. The company has developed branded versions of chemotherapeutic drugs with liposomal encapsulation. Lipoplatin is a nanoparticle consisting of cisplatin molecules (Cisplatin) encapsulated in liposomes. Cisplatin is the most widely used chemotherapeutic drug, the gold standard for epithelial tumors, representing more than 80% of human cancers. The drug developed by the company, especially tested for the treatment of pancreatic cancer and lung cancer, has anti-cancer efficacy more than 10-50 times higher than "traditional" drugs and treatment methods. In addition, many biotech and pharmaceutical companies around the world have tried to encapsulate Cisplatin into liposomes for the past 30 years with setbacks. In this regard, Regulon stands out as the only company that successfully solved the problem of encapsulating Cisplatin (this is the method of introducing one of the most common chemotherapy drugs Cisplatin for many types of cancer). The efficiency of encapsulation, developed according to the nanotechnological Regulon method, reached more than 97% in comparison with other methods (16-25%). Lipoplatin brought a revolution in classical chemotherapy because it does not affect healthy tissue after intravenous administration, concentrating in tumor tissue and metastases. Lipoplatin nanoparticles have the ability to unlock the cell membrane barrier, thereby emptying toxic payloads in the cancer cell, causing its death. Thus, the side effects of chemotherapy (often resulting in lethal outcomes) are dramatically reduced and the effectiveness of treatment is significantly increased. After intravenous administration of Lipoplatin, patients can perform their normal activities and even work on a regular basis.
LEADING SPECIALISTS IN THE FIELD OF ONCOLOGY WITH WHICH WE COOPERATE WORLDWIDE
Clinical development and research
Phase III (three) studies showed extremely low toxicity of “Lipoplatin” with improved therapeutic effect (index), especially for the treatment of non-small cell lung cancer (NSCLC). A filing for marketing authorization by the European Medicines Agency (EMA) for “Lipoplatin” under the name “NANOPLATIN” as first line treatment for lung cancer was applied in 2014. The company has also developed technologies for liposomal encapsulation of antibiotics and natural products with anti-cancer activity. The company's drugs are much more effective in treating malignant tumors due to their reduced toxicity and because of the ability to create higher concentrations of drugs in the tumor and in metastases compared with normal tissues, and this dramatically reduces the occurrence of undesirable side effects. Moreover. The technologies developed by the company are amenable to the use of gene therapy. This is a breakthrough in the field of molecular medicine, as it allows, in addition to effective cancer treatment, to successfully use these drugs against viral infections (for example, AIDS, hepatitis), as well as against fungal, protozoal and bactericidal infections, delivering antibiotics directly to the inflamed area. In addition, this technology has applications for cardiovascular diseases, arthritis and autoimmune processes, where changes in inflammatory vascular tissue also allow for “targeting” nanoparticles as a carrier of the appropriate drug for a specific disease.